Introduction to Gene Therapy
Welcome to your study guide for Gene Therapy, a key topic within Unit A2 5: Genetics, Stem Cell Research and Cloning for CCEA GCE Life and Health Sciences. Don't worry if genetic technologies seem daunting at first — by breaking down each concept step by step, you will master the principles, mechanisms, and real-world clinical applications needed for your exam.
In simple terms, our genes provide the biological instructions (the "recipe book") for building functional proteins and enzymes. When a person inherits a mutated, non-working gene, their cells produce a faulty protein or no protein at all, leading to a genetic disorder. Gene therapy is the medical technique developed to correct or bypass these genetic errors at the cellular level.
Key Takeaway: Gene therapy focuses on treating genetic conditions by introducing working genetic material into cells so they can produce the correct proteins.
1. Core Definition and Fundamental Principle
Official Definition: Gene therapy is the insertion of a normal, functional (unmutated) gene into target cells to replace, supplement, or counteract a defective or mutant gene that is causing a genetic disorder.
The Primary Objective: The goal is to restore the normal production of a correct, functional protein or enzyme, thereby treating, preventing, or significantly alleviating the symptoms of monogenic (single-gene) disorders.
An Everyday Analogy: Imagine trying to bake bread with a recipe card that is torn and missing the line about yeast. Your bread will never rise. Gene therapy does not necessarily scrub out the old recipe card; instead, it slips a clean, complete copy of the recipe into the kitchen so the baker can successfully make the bread.
2. Somatic vs. Germline Gene Therapy
In CCEA examinations, you must clearly distinguish between the two main types of gene therapy: Somatic Cell Gene Therapy and Germline Gene Therapy.
1. Somatic Cell Gene Therapy:
• Target Cells: Differentiated body cells (somatic cells), such as respiratory epithelial cells lining the lungs or bone marrow stem cells.
• Heritability: Not heritable. The introduced therapeutic gene is confined strictly to the patient's body tissues and is not passed on to future children.
• Duration of Effect: Temporary and short-lived. Somatic cells naturally age, die, and are shed over time. They are replaced by untreated progenitor cells, meaning the patient requires repeated, ongoing treatments.
• Legal and Ethical Status in the UK: Permitted and strictly regulated under clinical trials and approved medical treatments.
2. Germline Gene Therapy:
• Target Cells: Gametes (sperm or egg cells) or early-stage embryonic cells.
• Heritability: Heritable. The modified DNA is integrated into the reproductive cells and is passed down to all subsequent generations.
• Duration of Effect: Permanent. The new gene is copied during mitosis into every single cell derived from the modified zygote.
• Legal and Ethical Status in the UK: Illegal in humans due to ethical concerns, unknown long-term side effects, and unforeseen safety ramifications for unborn generations.
Comparison Summary Box:
• Target: Somatic = Body tissues (e.g. lung cells) | Germline = Gametes/Embryos
• Passed to Offspring? Somatic = No | Germline = Yes
• Treatment Longevity: Somatic = Requires repeated doses | Germline = Permanent
• UK Law: Somatic = Permitted & regulated | Germline = Illegal in humans
Memory Trick: Remember Somatic = Stays with the Single patient. Germline = Goes to the next Generation.
3. Vectors and Delivery Mechanisms
Naked DNA cannot easily enter human cells on its own because cell membranes repel large, negatively charged molecules. Scientists must use specialized delivery vehicles called vectors to carry the normal therapeutic gene into the target host cell's nucleus.
A. Viral Vectors
Viruses naturally infect human cells by injecting genetic material. In gene therapy, scientists modify viruses so they are replication-deficient (non-pathogenic, meaning they cannot reproduce or cause illness) and insert the normal human cDNA sequence into them.
• Adenoviruses: Engineered viruses that inject their DNA into target host cells without necessarily inserting it directly into the host chromosomes.
• Retroviruses / Lentiviruses: RNA viruses that convert their genetic material to DNA and integrate it into the host cell's genome.
• Mechanism: The modified virus binds to specific receptors on the surface of the target host cell and introduces the therapeutic gene directly into the cell.
B. Non-Viral Vectors (Liposomes)
• What are Liposomes? Liposomes are microscopic, spherical artificial vesicles surrounded by a phospholipid bilayer (lipid nanoparticles).
• How they carry DNA: The therapeutic recombinant plasmid DNA (carrying the normal gene) is encapsulated inside the hollow center of the liposome.
• Delivery Mechanism: Because the liposome's outer shell is made of a phospholipid bilayer just like the human cell surface membrane, the liposome easily fuses with the host cell membrane (or is taken up via endocytosis). This allows the plasmid DNA to enter the cytoplasm and travel to the nucleus.
Key Takeaway: Vectors act like postal delivery vans. Viral vectors use modified viral shells to inject genes, while liposomes use lipid bilayer bubbles that fuse directly with target cell membranes.
4. Applied Case Study: Cystic Fibrosis (CF)
CCEA consistently uses Cystic Fibrosis as the core model for examining somatic gene therapy. You must understand both the underlying biological cause of CF and how gene therapy is applied to treat it.
A. Cause and Pathology of Cystic Fibrosis
• Genetic Cause: Cystic Fibrosis is caused by an inherited recessive mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene.
• Cellular Defect: The normal CFTR gene codes for a channel protein that transports chloride ions (\(Cl^-\)) out of epithelial cells. In CF patients, this channel protein is non-functional or missing.
• Osmotic Consequence: Because chloride ions cannot move out of the epithelial cells into the surrounding mucus layer, water does not follow by osmosis. Instead, water remains inside the cells.
• Result: The mucus covering the respiratory tract and other epithelial linings becomes exceptionally thick and sticky.
B. Symptoms and Clinical Consequences of CF
• Gas Exchange Impairment: Thick mucus coats the alveoli and bronchioles, drastically reducing gaseous exchange and increasing the diffusion distance for oxygen and carbon dioxide.
• Recurrent Lung Infections: Pathogens and bacteria get trapped in the stagnant mucus and cannot be cleared by cilia, causing chronic, destructive chest infections.
• Digestive Problems: Thick mucus blocks the pancreatic ducts, preventing digestive enzymes from reaching the small intestine, leading to impaired digestion and malnutrition.
• Fertility Issues: Blockage of the vas deferens in males or thick cervical mucus in females can cause infertility.
C. Treating Cystic Fibrosis with Somatic Gene Therapy
1. A functional, normal CFTR gene is cloned and packaged inside a vector (such as a liposome or modified adenovirus).
2. The vector is administered to the patient via an aerosol inhaler (spray/nebuliser) directly into the respiratory tract.
3. The vectors bind to or fuse with the respiratory epithelial cells lining the lungs.
4. The host epithelial cells take up the DNA, transcribe and translate the normal gene, and synthesize functional CFTR channel proteins.
5. Chloride ion transport is restored, water moves by osmosis into the airway surface layer, and the mucus returns to a normal, watery consistency.
5. Technical Limitations and Clinical Challenges
In extended continuous-prose questions (assessing Quality of Written Communication), examiners frequently ask candidates to evaluate why gene therapy is not always 100% effective. You should be prepared to discuss these four core limitations:
1. Short Duration / Transience of Treatment:
Epithelial cells lining the respiratory tract have a naturally limited lifespan. They are continually worn away, shed (sloughed off), and replaced by unedited basal stem cells. Because somatic gene therapy does not alter these underlying progenitor cells, the therapeutic effect fades, requiring patients to undergo regular, repeated treatments.
2. Low Efficiency and Delivery Failure:
Aerosol mists only reach a small fraction of target lung cells. Furthermore, not all cells that encounter the vector will successfully take up the plasmid DNA, transport it into the nucleus, or express the CFTR protein in sufficient quantities.
3. Immune and Allergic Responses:
The human immune system recognizes viral vector proteins (or repeat vector doses) as foreign antigens. The immune system may mount an inflammatory or neutralising antibody response, destroying the vector before it can deliver the gene and potentially causing dangerous allergic reactions.
4. Insertional Mutagenesis (Oncogenesis):
When vectors integrate DNA randomly into the host genome, they run the risk of disrupting vital genes. If the vector inserts itself into a tumor suppressor gene or accidentally activates an adjacent oncogene, it can trigger uncontrolled cell division, leading to cancer or leukaemia.
6. Common Exam Pitfalls to Avoid
• Pitfall 1: Claiming the mutant gene is "cut out" or "edited". Standard somatic gene therapy delivers an additional, normal functional copy of the allele into the cell to supplement or override the faulty one; it does not typically slice out the existing defective gene.
• Pitfall 2: Saying treatment wears off without giving the biological reason. Never just write "it wears off." Always state that mature somatic epithelial cells naturally die and are shed, replaced by unmodified stem cells.
• Pitfall 3: Confusing Liposome entry with Viral entry. Liposomes fuse their phospholipid bilayer with the cell membrane; viruses bind to specific receptors to deliver their genetic cargo.
• Pitfall 4: Describing viruses as "living cells". Viruses are non-cellular infectious agents, not living cells.
7. Quick Revision Checklist
Can you answer these key CCEA questions without checking your notes?
• What is the primary objective of somatic gene therapy? (To restore production of a functional protein)
• Why is germline gene therapy illegal in the UK while somatic is permitted? (Heritable alterations pose unknown ethical and safety risks for future generations)
• How do liposomes deliver the CFTR gene to lung epithelial cells? (Phospholipid bilayer fuses with host cell membrane to release plasmid DNA)
• Why does CF cause thick mucus? (Defective CFTR protein prevents chloride ion transport, so water does not leave cells by osmosis)
• Name two risks associated with viral vectors. (Immune/allergic reaction and insertional mutagenesis/cancer)